- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Synonyms :
Class :
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may have an increased adverse effect when combined with caspofungin
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
when both drugs are combined, there may be an increased risk of adverse effects
may increase the toxicity of each other
may increase the toxicity of each other
may increase the myelosuppressive effect
may increase the nephrotoxic effect of fibric acid derivatives
may increase the nephrotoxic effect of tacrolimus
may increase the nephrotoxic effect of tacrolimus
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
estrogens esterified/methyltestosterone
may increase the hepatotoxic effect of androgens
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
oxymetholone decreases the metabolism and increases the effect of cyclosporine
danazol decreases metabolism and increases the effect of cyclosporine
methytestosterone decreases the metabolism and increases the effect of cyclosporine
methytestosterone decreases the metabolism and increases the effect of cyclosporine
May enhance the toxic effects of the other by pharmacodynamic synergism
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the levels of serum concentration of elagolix
may diminish the serum concentration
may enhance the serum concentration when combined
it decreases the concentration of eltrombopag in the serum
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
it increases the effect of neuromuscular blockage of neuromuscular-blocking agents
may enhance the serum concentration when combined with cyclosporine
may enhance the serum concentration when combined with cyclosporine
may enhance the serum concentration when combined with cyclosporine
may enhance the serum concentration when combined with cyclosporine
may enhance the serum concentration when combined with cyclosporine
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with cyclosporine
may enhance the concentration of serum when combined with cyclosporine
nafcillin will decrease the effect of action of cyclosporin by affecting enzyme CYP3A4 metabolism.
when cyclosporine and melphalan combine the immunosuppressive effects of both the drugs are enhanced and lead to increased risk of infection
may increase the hepatotoxic adverse effects of methotrexate by enhancing the serum concentration
may increase the hepatotoxic adverse effects of trimetrexate by enhancing the serum concentration
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance the serum level of docetaxel
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may alter the level by affecting CYP450 enzyme metabolism
may alter the level by affecting CYP450 enzyme metabolism
may enhance the serum concentration of CYP3A4 inhibitors
may increase the neurotoxic effects of imipenem
imipenem/cilastatin/relebactam
may increase the neurotoxic effects of imipenem
may increase the risk or severity of hypertension when combined
may increase the nephrotoxic effect when combined with cyclosporine
may increase the nephrotoxic effect when combined with cyclosporine
may have an increased nephrotoxic effect when combined with cyclosporine
may diminish the amount of P-glycoprotein (MDR1) efflux transporter